Sign in

Ryan Potts - real

@pottslab.bsky.social
1.4K followers 1.2K following 35 posts

VP & Head of Induced Proximity Platform, @Amgen | Scientist | Father

PostsRepliesMedia
Ryan Potts - real @pottslab.bsky.social · 03/10/2026
No cheating. Share the last photo of the sky from your camera roll.
310
Reposted by Ryan Potts - real
American Association for Cancer Research (AACR) @theaacr.bsky.social · 24/07/2026
David Puleo, Marina Nelen, Chinatsu Sakata, and Ryan Potts discussed "Degraders in the Era of Precision Oncology" in an #AACRdrugdev26 plenary session chaired by Danette Daniels. @danetteldaniels.bsky.social @pottslab.bsky.social
033
Ryan Potts - real @pottslab.bsky.social · 09/04/2026
Apply now to Amgen’s postbacc program!
152
Reposted by Ryan Potts - real
Science Magazine @science.org · 22/08/2025
A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.” Learn more: scim.ag/4lC2aCM
LOCKTACs comprise a subset of proximity drugs that stabilize naturally existing complexes. (A) Categories of proximity-based drugs. (B) Mechanism of PROTAC drugs. (C) LOCKTAC acting within a protein-protein interface. (D) LOCKTAC acting adjacent to a protein-protein interface. (E) Heterobifunctional LOCKTAC that does not bind at protein-protein interface. (F) Allosteric drugs induce conformational changes at a distance and are not LOCKTACs.
05514
Ryan Potts - real @pottslab.bsky.social · 22/08/2025
Check out how the Amgen Induced Proximity team repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @dnalawansha0509.bsky.social and team! #mycompany www.nature.com/articles/s41...
nature.com
LYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradation
Nature Communications - LYMTACs are heterobifunctional small molecules that take advantage of lysosomal membrane proteins to degrade membrane targets via relocalization and lysosomal degradation,...
0171
Ryan Potts - real @pottslab.bsky.social · 22/08/2025
www.science.org/doi/10.1126/...
science.org
Load and lock: An emerging class of therapeutics that influence macromolecular dissociation
Biology is governed by macromolecular interactions, perturbation of which often lies at the heart of disease. Most therapeutic drugs, whether they are small molecules or biologics, exert their effects...
052
Ryan Potts - real @pottslab.bsky.social · 22/08/2025
What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. science.org/doi/10.1126/sc…shorturl.at/976aj #mycompnay
science.org
2134
Ryan Potts - real @pottslab.bsky.social · 14/06/2025
🎓 Recent STEM grad? Jump-start your PhD journey with Amgen’s new 2-yr paid Postbaccalaureate Research Fellowship in Thousand Oaks! Work with world-class scientists, publish your findings, and make a real impact for patients. Apply by July 15 ➡️ amgen.wd1.myworkdayjobs.com/Careers/job/...
amgen.wd1.myworkdayjobs.com
Postbaccalaureate Fellow - Research
Career Category Research Job Description Join Amgen’s Mission of Serving Patients At Amgen, if you feel like you’re part of something bigger, it’s because you are. Our shared mission—to serve patients...
041
Reposted by Ryan Potts - real
Dan Nomura @dannomura.bsky.social · 10/06/2025
Our latest paper w/ @pottslab.bsky.social & @amgen.bsky.social in @jacs.acspublications.org by co-first authors @cmzammit.bsky.social & Cory Nadel on discovery of covalent destabilizing degrader of AR & AR-V7 in prostate cancer. Thanks also to @themarkfdn.bsky.social ! pubs.acs.org/doi/10.1021/...
0185
Ryan Potts - real @pottslab.bsky.social · 03/06/2025
Fabulous! Unfortunately, I’ll have to be there in spirit 👕 this year! Hoping to join at the next world tour 🚌 stop.
040
Reposted by Ryan Potts - real
Carolyn Bertozzi @carolynbertozzi.bskyverified.social · 11/04/2025
SCAM ALERT. This is a fake conference that ripped off my and other people’s names to trick people into registering. There is no such conference that I or the others shown were invited or agreed to. We are working to try to get this fraud taken down from the web. chemsymposia.com
chemsymposia.com
Join Chemsymposia 2026: Research & Innovation | ChemSymposia 2026
Join us at Chemsymposia 2026 to discover groundbreaking research in physics applications. Connect with experts, engage in insightful discussions, and explore our venue, registration details, and speak...
8192108
Reposted by Ryan Potts - real
Carolyn Bertozzi @carolynbertozzi.bskyverified.social · 28/03/2025
Now we’re finally talking! www.politico.com/news/2025/03...
politico.com
1517547
Reposted by Ryan Potts - real
Cell Chemical Biology @cp-cellchembiol.bsky.social · 21/03/2025
.@pottslab.bsky.social @amgen.bsky.social demonstrate proof-of-concept of disease-specific targeted degradation by redirecting virally encoded E3 ubiquitin ligases with VIPER-TACs. dlvr.it/TJgF0r
021
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
We anticipate that unbiased phenotypic screening in combination with biased E3-focused small molecule libraries will continue to be a fruitful approach to molecular glue discovery. This amazing work comes from a large team at @amgen.bsky.social in collaboration w/ @PlexiumTx. Congrats to all
000
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
SAR analysis provided the opportunity to directly test the impact of altering k-on and k-off rates, which revealed that slow k-off as far more important than fast k-on for degradation activity. 7/8
100
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
Comprehensive mutational analysis revealed the GEMIN3 degron by which dGEM3 mediates recognition by VHL. 6/8
100
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
We extensively characterize the properties of dGEM3 to show biochemical reconstitution of the VHL:dGEM3:GEMIN3 ternary complex and ubiquitination consistent with a molecular glue without pre-existing affinity between VHL and GEMIN3. 5/7
100
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
Proteomics analysis reveals dGEM3 is a highly selective degrader and the direct target is the SMN complex protein GEMIN3. 4/8
100
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
We discover dGEM3 as a VHL-based molecular glue causing significant gene expression changes. 3/8
100
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
We use an innovative gene expression read out approach to do target-agnostic screening of a focused 26,000 VHL ligand library for molecular glue degraders. 2/8
100
Ryan Potts - real @pottslab.bsky.social · 21/03/2025
🚨 Rational discovery of VHL molecular glues. New Preprint from @amgen.bsky.social Induced Proximity group led by postdoc Jonathan Bushman reports the discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq. Read on for details. 🧵1/8 www.biorxiv.org/content/10.1...
biorxiv.org
Discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq
Targeted protein degradation (TPD) is an emerging therapeutic modality in which small molecules are used to recruit targets to the natural protein degradation machinery of the cell. Molecular glue deg...
1326
Ryan Potts - real @pottslab.bsky.social · 20/03/2025
Check out this cover highlighting @amgen.bsky.social postdoc Kyle Mangano’s work on VIPER-TACs! 🐍
0121
Reposted by Ryan Potts - real
Sylvie Callegari @sylviecallegari.bsky.social · 13/03/2025
Thrilled to share the structure of dimerised human PINK1 docked to an endogenous translocase array on the mitochondrial surface, composed of two TOM complexes, bridged by a VDAC2 dimer! Published today in Science www.science.org/doi/10.1126/... @wehi-research.bsky.social @komanderlab.bsky.social
816856
Reposted by Ryan Potts - real
Sherry Pagoto, PhD @drsherrypagoto.bsky.social · 12/03/2025
New report shows that NIH grants fueled $95 billion in economic activity and 407,782 jobs in 2024. That's not to mention the countless lives that biomedical research has saved. Show me a better investment than that. www.forbes.com/sites/michae...
forbes.com
NIH Grants Fueled $95 Billion In FY 2024 Economic Activity, Finds New Report
National Institutes of Health grants generated almost $95 billion in economic activity nationwide in FY 2024 according to a new report by United for Medical Research.
2320221138
Reposted by Ryan Potts - real
Cell Chemical Biology @cp-cellchembiol.bsky.social · 05/03/2025
Online now! @pottslab.bsky.social @amgen.bsky.social demonstrate proof-of-concept of disease-specific targeted degradation by redirecting virally encoded E3 ubiquitin ligases with VIPER-TACs. dlvr.it/TJLmvh
043
Ryan Potts - real @pottslab.bsky.social · 05/03/2025
🚨Hiring Alert🚨 Recruiting an accomplished leader to serve as Director and Head of Discovery #Proteomics at Amgen. Find out more and apply here: careers.amgen.com/en/job/south...
careers.amgen.com
Director of Discovery Proteomics Jobs at Amgen in United States of America
Explore the details of a Director of Discovery Proteomics career in South San Francisco. Live. Win. Thrive. Search and apply for a rewarding new career at Amgen.
012
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
Thanks to all co-authors on this amazing Amgen-UCBerkeley Molecular Therapeutics Initiative collaboration, especially Charlotte Zammit, Cory Nadel, Ying Lin, and Sajjan Koirala. 7/7
020
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
Overall, these results indicated that EN1441 is a pathfinding molecule that directly engages AR-v7 Cys125, leading to destabilization and aggregation and the subsequent inhibition of AR transcriptional activity and ultimately ubiquitin-mediated proteasomal degradation. 6/7
110
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
Detailed mechanistic studies revealed that EN1441 promotes AR-v7 insolubility leading to aggregation that precedes degradation. 5/7
100
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
Further studies revealed that EN1441 inhibits AR-v7 transcriptional activity, leading to gene expression changes consistent with AR pathway inhibition. Importantly, this inhibition is more complete compared to therapies that only inhibit full-length AR and not AR-v7. 4/7
100
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
EN1441 directly engages AR-v7 Cys125 and causes proteasome-dependent degradation. 3/7
100
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
AR is a heavily drugged target in prostate cancer. A splice variant AR-v7 the occurs during the natural progression of disease has been challenging to drug. We performed a screen for AR-v7 degraders using a covalent fragment library leading to discovery of EN1441. 2/7
100
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
New @biorxivpreprint.bsky.social preprint from Amgen induced proximity group and @dannomura.bsky.social lab just posted that describes Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells. Read on for an overview 1/7 www.biorxiv.org/content/10.1...
biorxiv.org
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells
Androgen-independent prostate cancers, correlated with heightened aggressiveness and poor prognosis, are caused by mutations or deletions in the androgen receptor (AR) or expression of truncated varia...
1166
Ryan Potts - real @pottslab.bsky.social · 18/02/2025
Happy to share a @nature.com News and Views on the amazing discoveries by @brianliau.bsky.social & Ning Zheng labs on how a molecular glue unexpectedly mimics the effect of cancer mutations. Such cool science and with implications to drug discovery. Check it out. www.nature.com/articles/d41...
nature.com
Molecular glue unexpectedly mimics the effect of cancer mutations
Protein structures could guide the design of molecular glue degraders.
0279
Reposted by Ryan Potts - real
Dan Nomura @dannomura.bsky.social · 17/02/2025
Our latest BioRxiv by @cmzammit.bsky.social, Cory Nadel, @pottslab.bsky.social on a covalent destabilizing degrader against AR & AR-V7 in prostate cancer that targets an IDR C125 to destabilize, inhibit, and degrade TF! Thanks to @amgen.bsky.social, MTI, Berkeley MCB/Chemistry, NCI, TMFCR, and NSF!
biorxiv.org
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells
Androgen-independent prostate cancers, correlated with heightened aggressiveness and poor prognosis, are caused by mutations or deletions in the androgen receptor (AR) or expression of truncated varia...
0273
Reposted by Ryan Potts - real
Sri Kosuri @srikosuri.bsky.social · 08/02/2025
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.
841009846
Ryan Potts - real @pottslab.bsky.social · 08/01/2025
This is concerning please report the impersonation account
110
Reposted by Ryan Potts - real
Citizen.Coping @propcazhpm.bsky.social · 13/05/2024
Harvard and Google AI mapped one cubic millimeter of a human brain. It took up 1.4 petabytes of storage just in pictures of the specimen. So the entire brain would take ~ 1.6 zettabytes of storage, cost $50 billion, and require 140 acres. It would be the largest data center on the planet— one brain.
tomshardware.com
Full scan of 1 cubic millimeter of brain tissue took 1.4 petabytes of data, equivalent to 14,000 4K movies — Google's AI experts assist researchers
Mind-boggling mind research.
22728237
Ryan Potts - real @pottslab.bsky.social · 05/12/2024
Somatic FBXW7-R465C mutant shows promise in targeted protein degradation in cancer cells. This approach enhances protein degradation specificity in diseased cells. Congrats Xiaoyu Zhang and colleagues. 🧪 #chembio #TPD #CancerResearch www.biorxiv.org/content/10.1...
biorxiv.org
Harnessing the FBXW7 somatic mutant R465C for targeted protein degradation
Targeted protein degradation (TPD) is a pharmacological strategy that eliminates specific proteins from cells by harnessing cellular proteolytic degradation machinery. In proteasome-dependent TPD, exp...
0336
Reposted by Ryan Potts - real
Bluesky @bsky.app · 03/12/2024
Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪
456294864995
Reposted by Ryan Potts - real
Abhishek Chatterjee @achemsynbio.bsky.social · 01/12/2024
Got the chance to put together the "Click of Chemical Biologists" starter pack v1 and v2 over the Thanksgiving Break. Feel free to ping me on who else I might be missing! V1: go.bsky.app/3P5i7nJ V2: go.bsky.app/Cr4ej7
128232
Reposted by Ryan Potts - real
John Ngo @johntngo.bsky.social · 30/11/2024
We designed MS2 and PP7 binding coat proteins that are degraded in cells except when bound by their hairpin RNAs. You can check out our pre-print here: tinyurl.com/27p7hyt9, and listen to a Google AI-generated podcast on it here: notebooklm.google.com/notebook/d71...
511943
Reposted by Ryan Potts - real
Zunlong Ke @zunlongke.bsky.social · 29/11/2024
A fun journey of full-length EGFR with Dan Leahy and @edwardmarcotte.bsky.social at UT Austin @utaustin.bsky.social. See below: Structure and organization of full-length Epidermal Growth Factor Receptor in extracellular vesicles by cryo-electron tomography www.biorxiv.org/content/10.1...
69324
Ryan Potts - real @pottslab.bsky.social · 27/11/2024
Nifty, innovative approach
042
Reposted by Ryan Potts - real
Xiuzhen Chen @xiuzhenchen.bsky.social · 27/11/2024
Came to a new understanding of 'colocalization' since starting STED microcopy: there is no colocalizaiton, objects cannot occupy the same physical space!
013
Reposted by Ryan Potts - real
Ingo Hartung @hartungingo.bsky.social · 26/11/2024
If you are not yet sure how to best spend your time in May next year, come to Chicago & hear about small molecule drug discovery. It‘s where all the cool stuff is currently happening (I may be slightly biased in my opinion). www.medchemfrontiers.org/@acsmedi.bsk...
073
Reposted by Ryan Potts - real
Witold Szymański @witek-teammassspec.bsky.social · 26/11/2024
Just got my TimsTof Ultra cookie form 😏 a nice touch from #bruker
5295
Reposted by Ryan Potts - real
bioRxiv Biochemistry @biorxiv-biochem.bsky.social · 26/11/2024
Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12 www.biorxiv.org/content/10.1101/202…
biorxiv.org
Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12 https://www.biorxiv.org/content/10.1101/2024.11.25.625235v1
The oxidative stress response is centered on the transcription factor NRF2 and protects cells from r
0114
Reposted by Ryan Potts - real
Ingo Hartung @hartungingo.bsky.social · 25/11/2024
There are no shortcuts in drug discovery. And it takes incredible efforts to make sense of what you can find in the scientific literature. This is an excellent piece of work to quality check what has been claimed as a new avenue in targeted protein degradation (TPD). www.nature.com/articles/s41...
nature.com
Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets - Nature Communications
Autophagosome tethering compounds (ATTECs) are small molecule degraders hijacking the autophagy system. Here, the authors show that current ATTEC ligands did not bind to their designated targets but e...
27724
Reposted by Ryan Potts - real
ᐯIᑕTOᖇ ᑎIᘔET, ᗰᗪ @nizet.bsky.social · 21/11/2024
in-frame deletion #genetics
326339